Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility

Endocrinology

Volumn 153, Issue 12, 2012, Pages 5980-5992

  Ratner, Laura D ^a   Gonzalez, Betina ^a   Ahtiainen, Petteri ^b   Di Giorgio, Noelia P ^a   Poutanen, Matti ^b   Calandra, Ricardo S ^a   Huhtaniemi, Ilpo T ^b,c   Rulli, Susana B ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSITY OF TURKU   (Finland)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE MESILATE; CABERGOLINE; CHORIONIC GONADOTROPIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLINE; ESTRADIOL; PROGESTERONE; PROLACTIN; TESTOSTERONE; TRANSCRIPTION FACTOR E2F1;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISORDERS OF HORMONE METABOLISM; DRUG EFFECT; DRUG EFFICACY; ESTRUS CYCLE; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; GENE EXPRESSION; GONAD DYSFUNCTION; HORMONE BLOOD LEVEL; HYPERANDROGENISM; HYPERPROGESTERONEMIA; HYPERPROLACTINEMIA; HYPOPHYSIS; LONG TERM CARE; MOUSE; NONHUMAN; OBESITY; OVULATION; PHENOTYPE; PRIORITY JOURNAL; SHORT COURSE THERAPY;

ANIMALS; BROMOCRIPTINE; CHORIONIC GONADOTROPIN; DISEASE MODELS, ANIMAL; ERGOLINES; FEMALE; FERTILITY; GENE EXPRESSION REGULATION; HUMANS; HYPERPROLACTINEMIA; INFERTILITY; MICE; MICE, TRANSGENIC; OVULATION; PHENOTYPE; TIME FACTORS;

EID: 84870217595     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1393     Document Type: Article

References (62)

1. Bachelot A, Binart N 2007 Reproductive role of prolactin. Reproduction 133:361-369
2. Ben-Jonathan N, LaPensee CR, LaPensee EW 2008 What can we learn from rodents about prolactin in humans? Endocr Rev 29:1-41
3. Yazigi RA, Quintero CH, Salameh WA 1997 Prolactin disorders. Fertil Steril 67:215-225
4. Moult PJ, Rees LH, Besser GM 1982 Pulsatile gonadotrophin secretion in hyperprolactinaemic amenorrhoea and the response to bromocriptine therapy. Clin Endocrinol (Oxf) 16:153-162
5. Grattan DR, Jasoni CL, Liu X, Anderson GM, Herbison AE 2007 Prolactin regulation of gonadotropin-releasing hormone neurons to suppress luteinizing hormone secretion in mice. Endocrinology 148:4344-4351
6. Anderson GM, Kieser DC, Steyn FJ, Grattan DR 2008 Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol. Endocrinology 149:1562-1570
7. Horseman N, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E, Dorshkind K 1997 Defective mammopoiesis, but normal hematopoiesis, in mice with targeted disruption of the prolactin gene. EMBO J 16:6926-6935
8. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, Edery M, Brousse N, Babinet C, Binart N, Kelly PA 1997 Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 11:167-178
9. Grosdemouge I, Bachelot A, Lucas A, Baran N, Kelly PA, Binart N 2003 Effects of deletion of the prolactin receptor on ovarian gene expression. Reprod Biol Endocrinol 1:12
10. Stocco C, Telleria C, Gibori G 2007 The molecular control of corpus luteum formation, function, and regression. Endocr Rev 28:117-149
11. Ben-Jonathan N, Hnasko R 2001 Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22:724-763
12. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO 1985 Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698-705
13. Gillam MP, Molitch ME, Lombardi G, Colao A 2006 Advances in the treatment of prolactinomas. Endocr Rev 27:485-534
14. Webster J, Piscittelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative groups. N Engl J Med 331:904-909
15. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A 2001 Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256-5261
16. dos Santos Nuñes V, El Dib R, Boguszewski CL, Nogueira CR 2011 Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 14:259-265
17. Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S, Okada Y, Hori T 2010 Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95:2672-2679
18. Negishi H, Koide SS 1997 Prevention and termination of pregnancy in rats by cabergoline a dopamine agonist. J Reprod Fertil 109:103-107
19. Xu RK, Wu XM, Di AK, Xu JN, Pang CS, Pang SF 2000 Pituitary prolactin-secreting tumor formation: recent developments. Biol Signals Recept 9:1-20
20. Moro M, Inada Y, Miyata H, Komatsu H, Kojima M, Tsujii H2 001 Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats. Clin Exp Pharmacol Physiol 28:651-658
21. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, Allen RG, Hnasko R, Ben-Jonathan N, Grandy DK, Low MJ 1997 Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 19:103-113
22. Themmen APN, Huhtaniemi IT 2000 Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 21:551-583
23. Rulli SB, Kuorelahti A, Karaer O, Pelliniemi LJ, Poutanen M, Huhtaniemi I 2002 Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin. Endocrinology 143:4084-4095
24. Rulli SB, Ahtiainen P, Mäkelä S, Toppari J, Poutanen M, Huhtaniemi I 2003 Elevated steroidogenesis, defective reproductive organs, and infertility in transgenic male mice overexpressing human chorionic gonadotropin. Endocrinology 144:4980-4990
25. Rulli SB, Huhtaniemi I 2005 What have gonadotrophin overexpressing transgenic mice taught us about gonadal function? Reproduction 130:283-291
26. Kuorelahti A, Rulli S, Huhtaniemi I, Poutanen M 2007 Human chorionic gonadotropin (hCG) up-regulates wnt5b and wnt7b in the mammary gland, and hCGβ transgenic female mice present with mammary gland tumors exhibiting characteristics of the Wnt/β-catenin pathway activation. Endocrinology 148:3694-3703
27. Ahtiainen P, Sharp V, Rulli SB, Rivero-Müller A, Mamaeva V, Röyttä M, Huhtaniemi I 2010 Enhanced LH action in transgenic female mice expressing hCGβ-subunit induces pituitary prolactinomas: the role of high progesterone levels. Endocr Relat Cancer 17:611-621
28. Tanaka K, Ogawa N 2005 Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice. Neurosci Res 51:9-13
29. Nelson JF, Felicio LS, Randall PK, Sims C, Finch CE 1982 A longitudinal study of estrous cyclicity in aging C57BL/6J mice: I. Cycle frequency, length and vaginal cytology. Biol Reprod 27:327-339
30. Gonzalez B, Ratner LD, Di Giorgio NP, Poutanen M, Huhtaniemi I, Calandra RS, Lux-Lantos VA, Rulli SB 2011 Effect of chronically elevated androgens on the developmental programming of the hypothalamic-pituitary axis in male mice. Mol Cell Endocrinol 332: 78-87
31. Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
32. Zhang W, Murao K, Imachi H, Iwama H, Chen K, Fei Z, Zhang X, Ishida T, Tamiya T 2010 Suppression of prolactin expression by cabergoline requires prolactin regulatory element-binding protein (PREB) in GH3 cells. Horm Metab Res 42:557-561
33. Frost SJ, Simpson DJ, Farrell WE 2001 Decreased proliferation and cell cycle arrest in neoplastic rat pituitary cells is associated with transforming growth factor-β1-induced expression of p15/INK4B. Mol Cell Endocrinol 176:29-37
34. Ahtiainen P, Rulli SB, Shariatmadari R, Pelliniemi LJ, Toppari J, Poutanen M, Huhtaniemi IT 2005 Fetal but not adult Leydig cells are susceptible to adenoma formation in response to persistently high hCG level: a study on hCG overexpressing transgenic mice. Oncogene 24:7301-7309
35. Eguchi K, Kawamoto K, Uozumi T, Ito A, Arita K, Kurisu K 1995 In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors. Endocr J 42:153-161
36. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G 2000 Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247-2252
37. Yavasoglu I, Kucuk M, Coskun A, Guney E, Kadikoylu G, Bolaman Z 2009 Polycystic ovary syndrome and prolactinoma. Intern Med 48:611-613
38. Risma KA, Clay CM, Nett TM, Wagner T, Yun J, Nilson JH 1995 Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc Natl Acad Sci USA 92:1322-1326
39. Ishida M, Choi JH, Hirabayashi K, Matsuwaki T, Suzuki M, Yamanouchi K, Horai R, Sudo K, Iwakura Y, Nishihara M 2007 Reproductive phenotypes in mice with targeted disruption of the 20α-hydroxysteroid dehydrogenase gene. J Reprod Dev 53:499-508
40. Risk M, Gibori G 2001 Mechanisms of luteal cell regulation by prolactin. In: Horseman ND, ed. Prolactin. Boston: Kluwer; 265-295
41. Gibori G, Richards JS 1978 Dissociation of two distinct luteotropic effects of prolactin: regulation of luteinizing hormone-receptor content and progesterone secretion during pregnancy. Endocrinology 102:767-774
42. Lux VA, Tesone M, Larrea GA, Libertun C 1984 High correlation between prolactinemia, 125-I hLH binding and progesterone secretion by an experimental luteoma. Life Sci 35:2345-2352
43. Albarracin CT, Parmer TG, Duan WR, Nelson SE, Gibori G 1994 Identification of a major prolactin-regulated protein as 20α- hydroxysteroid dehydrogenase: coordinate regulation of its activity, protein content, and messenger ribonucleic acid expression. Endocrinology 134:2453-2460
44. Bachelot A, Beaufaron J, Servel N, Kedzia C, Monget P, Kelly PA, Gibori G, Binart N 2009 Prolactin independent rescue of mouse corpus luteum life span: identification of prolactin and luteinizing hormone target genes. Am J Physiol Endocrinol Metab 297:E676-E684
45. Manno M, Tomei F, Marchesan E, Adamo V 2005 Cabergoline: safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol 122:127-128
46. Youssef MA, van Wely M, Hassan MA, Al-Inany HG, Mochtar M, Khattab S, van der Veen F 2010 Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 16:459-466
47. Spitzer D, Wogatzky J, Murtinger M, Zech MH, Haidbauer R, Zech NH 2011 Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome. Fertil Steril 95:2742-4.e1
48. Papaleo E, Doldi N, De Santis L, Marelli G, Marsiglio E, Rofena S, Ferrari A 2001 Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Hum Reprod 16:2263-2266
49. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, Remohi J, Simon C, Pellicer A 2006 Low-dose dopamine agonist administraion blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 147:5400-5411
50. Gómez R, Ferrero H, Delgado-Rosas F, Gaytan M, Morales C, Zimmermann RC, Simón C, Gaytan F, Pellicer A 2011 Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment. J Clin Endocrinol Metab 96:2484-2492
51. Drange MR, Fram NR, Herman-Bonert V, Melmed S 2000 Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab 85:168-174
52. Heaney AP, Fernando M, Melmed S 2002 Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest 109:277-283
53. Piroli G, Weisenberg LS, Grillo C, De Nicola AF 1990 Subcellular distribution of cyclic adenosine 3′,5′-monophosphate-binding protein and estrogen receptors in control pituitaries and estrogen-induced pituitary tumors. J Natl Cancer Inst 82:596-601
54. An JJ, Cho SR, Jeong DW, Park KW, Ahn YS, Baik JH 2003 Antiproliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 206:49-62
55. Greenman Y, Tordjman K, Stern N 1998 Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 48:547-553
56. Galluzzi F, Salti R, Stagi S, La Cauza F, Chiarelli F 2005 Reversible weight gain and prolactin levels - long-term follow-up in childhood. J Pediatr Endocrinol Metab 18:921-924
57. Naliato EC, Violante AH, Caldas D, Lamounier Filho A, Loureiro CR, Fontes R, Schrank Y, Souza RG, Costa PL, Colao A 2007 Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol (Oxf) 67:845-852
58. Gibson CD, Karmally W, McMahon DJ, Wardlaw SL, Korner J 2012 Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metab 14:335-340
59. Byatt JC, Staten NR, Salsgiver WJ, Kostelc JG, Collier RJ 1993 Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol Endocrinol Metab 264:E986-E992
60. Noel MB, Woodside B 1993 Effects of systemic and central prolactin injections on food intake, weight gain, and estrous cyclicity in female rats. Physiol Behav 54:151-154
61. Freemark M, Fleenor D, Driscoll P, Binart N, Kelly PA 2001 Body weight and fat deposition in prolactin receptor-deficient mice. Endocrinology 142:532-537
62. Egli M, Leeners B, Kruger TH 2010 Prolactin secretion patterns: basic mechanisms and clinical implications for reproduction. Reproduction 140:643-654